Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New chip may pick better sperm for IVF, study hopes to find out

NCT ID NCT07093619

Knowledge-focused Sponsor: ART Fertility Clinics LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares a new microfluidic sperm-sorting chip (FERTILE Plus) to the standard density gradient method for preparing sperm used in IVF with genetic testing (PGT-A). Researchers will measure how long each method takes and whether embryos made with chip-sorted sperm are more likely to be chromosomally normal. The trial enrolls 100 women undergoing IVF, using a split-sample design so each sperm sample is processed both ways.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
FERTILE Plus microfluidic sperm sorting chip
What this could lead to
If microfluidic sperm preparation proves faster and yields more chromosomally normal embryos, it could become a standard technique in IVF labs, potentially improving success rates.
What could go wrong
This is a small, early-stage study (100 participants) comparing two lab methods. Even if microfluidics shows benefits here, results may not translate to higher live birth rates or apply to all fertility cases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Women with at least 8 MII per cycle after denudation (AFC≥8). 2. Women of all ages. 3. All embryo qualities ≥BL3CC at the time of biopsy on day 5, 6 and/or 7. 4. Fresh sperm used from ejaculate with a concentration ≥1 mill/ml and ≥10% motility (A+B). 5. Sperm samples with a minimum of 2 ml. Exclusion Criteria: * Frozen oocytes samples with severe oligospermia (≤1mill/ml). * PGT-M cases * Sperm with \> 1M/ml of round cells

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ICSI are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ICSI PGT-A Semen analysis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • ART Fertility Clinics LLC

    RECRUITING

    Abu Dhabi, Abu Dhabi Emirate, 60202, United Arab Emirates

More trials for these conditions

Other studies related to the condition(s) this trial covers.